Cargando…
The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
BACKGROUND: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China. METHODS: A total of 4760 hospitalized...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345993/ https://www.ncbi.nlm.nih.gov/pubmed/28293117 http://dx.doi.org/10.2147/IJGM.S128047 |
_version_ | 1782513817601703936 |
---|---|
author | Zheng, Huan Jie Ouyang, Shu Kun Zhao, Yue Lu, Kai Luo, Su Xin Xiao, Hua |
author_facet | Zheng, Huan Jie Ouyang, Shu Kun Zhao, Yue Lu, Kai Luo, Su Xin Xiao, Hua |
author_sort | Zheng, Huan Jie |
collection | PubMed |
description | BACKGROUND: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China. METHODS: A total of 4760 hospitalized patients with AF were enrolled from 21 hospitals in Chongqing city from January 1 to December 31, 2013. RESULTS: Among the enrolled patients, 3785 were diagnosed with nonvalvular AF. These patients had a mean age of 74.4±10.1 years. The mean CHADS(2) score of all subjects was 2.60±1.34, and 80.7% of the patients had CHADS(2) ≥2. The use rate of OACs was only 11.5% for patients with a high risk for stroke (CHADS(2) ≥2) and was much lower in patients from the second-level hospitals than in patients from the third-level hospitals (5.8% vs. 16.9%, P<0.001). The leading reason for the underuse of OACs in high-risk patients was physician’s nonfeasance. CONCLUSION: This study demonstrated that the underuse of anticoagulation therapy in hospitalized patients with nonvalvular AF was particularly serious in Southwest China, especially in the second-level hospitals. Urgent and effective measures are desperately needed to improve this alarming situation in China. |
format | Online Article Text |
id | pubmed-5345993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53459932017-03-14 The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China Zheng, Huan Jie Ouyang, Shu Kun Zhao, Yue Lu, Kai Luo, Su Xin Xiao, Hua Int J Gen Med Original Research BACKGROUND: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China. METHODS: A total of 4760 hospitalized patients with AF were enrolled from 21 hospitals in Chongqing city from January 1 to December 31, 2013. RESULTS: Among the enrolled patients, 3785 were diagnosed with nonvalvular AF. These patients had a mean age of 74.4±10.1 years. The mean CHADS(2) score of all subjects was 2.60±1.34, and 80.7% of the patients had CHADS(2) ≥2. The use rate of OACs was only 11.5% for patients with a high risk for stroke (CHADS(2) ≥2) and was much lower in patients from the second-level hospitals than in patients from the third-level hospitals (5.8% vs. 16.9%, P<0.001). The leading reason for the underuse of OACs in high-risk patients was physician’s nonfeasance. CONCLUSION: This study demonstrated that the underuse of anticoagulation therapy in hospitalized patients with nonvalvular AF was particularly serious in Southwest China, especially in the second-level hospitals. Urgent and effective measures are desperately needed to improve this alarming situation in China. Dove Medical Press 2017-03-03 /pmc/articles/PMC5345993/ /pubmed/28293117 http://dx.doi.org/10.2147/IJGM.S128047 Text en © 2017 Zheng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zheng, Huan Jie Ouyang, Shu Kun Zhao, Yue Lu, Kai Luo, Su Xin Xiao, Hua The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China |
title | The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China |
title_full | The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China |
title_fullStr | The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China |
title_full_unstemmed | The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China |
title_short | The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China |
title_sort | use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in southwest china |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345993/ https://www.ncbi.nlm.nih.gov/pubmed/28293117 http://dx.doi.org/10.2147/IJGM.S128047 |
work_keys_str_mv | AT zhenghuanjie theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT ouyangshukun theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT zhaoyue theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT lukai theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT luosuxin theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT xiaohua theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT zhenghuanjie usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT ouyangshukun usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT zhaoyue usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT lukai usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT luosuxin usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina AT xiaohua usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina |